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Abstract
·AIM: To evaluate the long-term efficacy and safety of
dexamethasone implants in subjects affected by diabetic
macular edema (DME) resistant to anti -vascular
endothelial growth factor (VEGF) therapy.
·METHODS: Thirty-two DME patients were enrolled. A
700 microgram slow release Intravitreal Dexamethasone
Implant (Ozurdex誖 ) was placed in the vitreous cavity. All
patients were followed for 18mo. Best -corrected visual
acuity (BCVA) measured with Early Treatment Diabetic
Retinopathy Study (ETDRS) and central macular
thickness (CMT) exams were carried out at baseline (T0)
and after 1 (T1), 3 (T3), 4 (T4), 6 (T6), 9 (T9), 12 (T12), 15
(T15), and 18mo (T18) post injection.
· RESULTS: Repeated measures ANOVA showed an
effect of treatment on ETDRS ( <0.0001). Post hoc
analyses revealed that ETDRS values were significantly
increased at T1, T3, T4, T9, and T15 ( <0.001) as
compared to baseline value (T0). At T6, T12, and T18,
ETDRS values were still statistically higher than baseline
( <0.001 T0). However, at these time points, we
observed a trend to return to baseline conditions.
ANOVA also showed an effect of treatment ( <0.0001).
CMT decreased significantly at T1, T3, T4, T9, and T15
( <0.001). At T6 ( <0.01), T12 and T18 ( <0.001) CMT
was also significantly lower than T0 although a trend to
return to the baseline conditions was also observed.
·CONCLUSION: Our findings demonstrate that Intravitreal
Dexamethasone Implant is a good option to improve
BCVA and CMT in DME patients resistant to anti -VEGF
therapy. Our data also show that the use of drugs
administered directly into the vitreous allows achieving
appropriate and long-lasting concentration at the site of
disease without systemic side effects.
· KEYWORDS: diabetic macular edema; Intravitreal
Dexamethasone Implant; anti-vascular endothelial growth
factor therapy
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INTRODUCTION
D iabetic macular edema (DME) is one of the leadingcauses of visual loss in diabetes [1]. DME represents the
first change occurring in the retina, leading to reduced visual
acuity and breakdown of the blood-retinal barrier[2]. Increased
glucose levels can induce numerous biochemical and
metabolic changes contributing to endothelial dysfunction,
inflammatory processes and increased trans-vascular passage
of macromolecules [3-4]. All these factors contribute to
disruption of the blood-retinal barrier, accumulation of free
radicals, activation of vascular endothelial growth factor
(VEGF) pathway in endothelial intercellular junctions,
pericyte loss, and retinal vessel leukostasis[5-7].
To date, the goals of local eye treatment are the diminution of
macular edema, to stop the disease progression and, possibly,
to improve the vision. Intravitreal injections of anti-VEGF
agents is the current treatment of choice in DME [7-8]. Other
therapeutic options are vitrectomy, protein kinase C (PKC)
inhibitors and steroids[7,9-11].
Dexamethasone is one of the most potent glucocorticoid
available in ophthalmology [12]. It exerts anti-inflammatory,
anti-angiogenic, anti-edematous and anti-proliferative effects
by influencing several signal transduction pathways [13].
Dexamethasone stabilizes the blood-retinal barrier
modulation of proteins involved in VEGF receptor
downstream pathway [14]. Previous study [15] has shown that
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intravitreal injection of dexamethasone improves DME by
inhibiting leukostasis and decreasing synthesis and
expression of intracellular adhesion molecule-1 (ICAM-1).
Moreover, it has been shown that activation of glucocorticoid
receptor may protect the retinal photoreceptors through an
anti-apoptotic action[16].
The dexamethasone implant (Ozurdex, Allergan Inc., Irvine,
CA, USA) is a new therapeutic approach approved in Italy
for the intravitreal treatment of macular edema after vascular
retinal occlusions [17]. Due to its progressively biodegradable
form of lactic and glycolic acid copolymers, it is found in
good concentrations in the vitreous chamber for a period of
up to 180d after a single injection[18-19].
One study has shown that Intravitreal Dexamethasone
Implant is efficient in patients with recalcitrant macular
edema secondary to retinal vein occlusion[20]. In addition, data
on the long term efficacy and safety of dexamethasone
implant in DME have been provided in the study of Haller
[21] and, more recently, in that of Mastropasqua [22].
In order to confirm these data and provide further evidence
for the use of dexamethasone in DME, in this study we
evaluated the efficacy and safety of dexamethasone implant
injections in patients affected by DME resistant to anti-VEGF
therapy (loading phase), as ascertained by optical coherence
tomography (OCT) showing no signs of improvements in
central macular thickness (CMT) and best-corrected visual
acuity (BCVA).
SUBJECTS AND METHODS
Subjects From 4/2014 to 9/2015, thirty-two type 2 diabetic
patients (32 eyes) were enrolled in this retrospective study.
Demographic data of the patients, duration of DME and type
2 diabetes are reported in Table 1. The presence of macular
ischemia was evaluated at baseline with fluorescein
angiography. Evaluation of the integrity of external limiting
membrane (ELM) and ellipsoid zone (EZ) of the
photoreceptor interface was performed by OCT at baseline,
6, 12 and 18mo after dexamethasone treatment.
The study was approved by the Ethics Committee of the
University of Rome "La Sapienza" and was performed in
accordance with the ethical standards of the Declaration of
Helsinki. A written informed consent was obtained from each
patient.
All patients underwent general preoperative anamnesis, and
blood tests including glycosilated Hb (HbA1c). All patients
gave their informed consent to the injection and were
followed for 18mo.
Treatment All recruited patients had previously undergone
a cycle of treatment (loading phase of three monthly
intravitreal injections) with anti-VEGF: sixteen with
bevacizumab (Avastin 誖 ; Genentech, Inc., South San
Francisco, CA, USA), thirteen with ranibizumab (Lucentis誖 ;
Genentech, Inc., South San Francisco, CA, USA) and three
with pegaptanib (Macugen誖 ; Eyetech Pharmaceuticals, Inc.,
New York, NY, USA). No combination of these therapies
were given.
Resistance to anti-VEGF therapy was determined by clinical
parameters and OCT data. In absence of improvements of
central macular thickness (CMT) and BCVA values after the
loading phase of anti-VEGF treatment, the patient was
classified as resistant to therapy. All intravitreal therapies
were suspended 3mo before the beginning of the study.
During the study period, none of the patients received
additional therapy, except for a prophylactic antibiotic
therapy (6d) starting 1d before the intravitreal dexamethasone
injection.
Inclusion Criteria Criteria for inclusion were: age (18y;
persistent DME; BCVA between 5 [corresponding to 1/10,
logarithm of the minimum angle of resolution (logMAR) 1.0
or more] and 40 (corresponding to 5/10, logMAR 0.3 or less)
letters; macular edema with thickness (285 滋m measured by
spectral domain HRA-OCT with a volumetric 512伊49-scan
(Heidelberg Engineering, Germany) system. The mean BCVA
at T0 was 16.54依10.85 letters and CMT was 521.8依174.5滋m.
Evaluations Baseline vision evaluation was carried out pre-
therapy at T0. Fluorangiography (FAG) evaluated the
presence of macular ischemia, while BCVA was measured
with Early Treatment Diabetic Retinopathy Study (ETDRS)
tables placed at a distance of 4 m. Slit lamp biomicroscopy
evaluated the lens opacity. Ocular tonometry (using a
Goldman applanation tonometer) was used to determine the
intraocular pressure (IOP). Fundus biomiocrosopy and color
fundus photography were utilized to evaluate the objective
state of the retina. OCT was used for measurement of
macular thickness and morphology using a Spectralis
HRA-OCT produced by Heidelberg Engineering with a
volumetric 512伊49-scan.
BCVA and CMT exams were carried out at baseline (T0)
and after 1 (T1), 3 (T3), 4 (T4), 6 (T6), 9 (T9), 12 (T12), 15
(T15), and 18mo (T18) post injection.
Efficacy Criteria Primary outcome measures included
mean BCVA and CMT values at baseline and at all
follow-up visits. The implant was considered efficient when a
mean improvement of BCVA 逸10 letters (2 lines) ETDRS
was observed.
Table 1 Demographic and clinical features of subjects with persistent 
DME 
Demographic and clinical features Average  
Age (a) 66.34±9.35 
Gender 23M/9F 
Eyes (n) 32 
Duration of type 2 diabetes (a) 18.12±6.49 
Duration of DME (mo) 41.94±18.39 
DME: Diabetic macular edema. Data are expressed as mean±standard 
deviation.   
Intravitreal dexamethasone in DME for 18mo
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Secondary outcomes were the analysis of the retinal layer
structure using OCT. The outcomes expected were: a
reduction of CMT 逸250 滋m. The evaluation of the integrity
of ELM and EZ of the photoreceptor interface was carried
out at baseline, 6, 12 and 18mo.
Intravitreal Dexamethasone Implant All implants were
performed under sterile conditions. Povidone-iodine solution
(5% ) and topical anesthetic (ropivacaine) were used to
prepare the conjunctiva and the blepharostat was positioned.
A 700 microgram Intravitreal Dexamethasone Implant
(Ozurdex®) at slow release was placed in the vitreal cavity,
behind the crystalline lens [11-14,23]. A topical ophthalmic
antibiotic was administered for 7d after treatment.
Local or systemic side effects caused by the implant were
monitored for the entire study time.
Safety Criteria The insurgence of undesired side-effects
correlated to the drug ( inflammation of the anterior
chamber; ocular pain; keratitis or vitreous opacity; increase
in IOP and insurgence of cataract) was monitored monthly.
Side effects correlated to the surgical intervention (
endophthalmitis; perforation of the eye; conjunctival
hemorrhage and systemic effects related to the drug) were
also monitored monthly.
Re -injection Criteria Patients showing a worsening of
clinical/functional condition (a reduction of at least 0.2 or 10
letters or an increase of macular thickness of at least 150 滋m)
after 4mo were recommended for a retreatment.
Statistical Analysis Data were analyzed by repeated
measures ANOVA. Posthoc analyses were performed with
Fisher's protected least significant difference. The
significance level was set at a -value <0.05. StatView
software from SAS Institute was used.
RESULTS
Number of Dexamethasone Injections Performed During
the Follow-up Period In all patients, we observed that the
BCVA and CMT values tended to return to baseline levels
after 6mo from injection. Thus, according to the re-injection
criteria defined above, all patients underwent a reinjection of
dexamethasone implant during each semester of the
follow-up. Thus, all patients received a total of four
dexamethasone injections during the time of the study: at
baseline (T0), 6 (T6), 12 (T12) and 18mo (T18).
Visual Acuity Measured with Early Treatment Diabetic
Retinopathy Scale The BCVA was measured using the
ETDRS. The response to treatment was evaluated
independently of sex, age, and comorbidities.
ANOVA showed a significant effect of the treatment on
ETDRS ( <0.0001) (Figure 1). Post hoc analyses revealed
that ETDRS values were significantly increased at T1, T3,
T4, T9, and T15 ( <0.001) as compared to baseline value
(T0). At T6, T12, and T18, ETDRS values were still
statistically higher than baseline ( <0.001 T0). However,
at these time points, we observed a trend to return to baseline
conditions (Figure 1).
Central Macular Thickness As for ETDRS values,
repeated measures ANOVA also showed a significant effect
of Intravitreal Dexamethasone Implant ( <0.0001) (Figure 2).
CMT decreased significantly at T1, T3, T4, T9, and T15
( <0.001). At T6 ( <0.01), T12 and T18 ( <0.001) CMT
was also significantly lower than T0 although a trend to
return to the baseline conditions was also observed.
Complications None of the patients had uncontrolled
hypertension, hyperlipidemia, renal disease, or other
comorbidities at admission and in the successive follow-up.
The IOP values registered during the 18mo of follow-up did
not show significant increments. In 5 patients, IOP was
higher than 21 mm Hg, and this condition was successfully
treated with beta-blocker drugs.
Twenty-six patients were pseudophakic. The remaining 6
patients did not show lens opacities at baseline. At the end of
Figure 1 ETDRS in patients affected by persistent DME and
treated with Intravitreal Dexamethasone Implant (Ozurdex誖 )
over 18mo Data are the mean依SEM. Data are expressed in letters
(ETDRS values). a <0.001.
Figure 2 CMT in patients affected by persistent DME and
treated with Intravitreal Dexamethasone Implant (Ozurdex誖 )
over 18mo Data are the mean依SEM. Values are expressed in 滋m.
b <0.01; c <0.001.
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follow up, these patients showed a nuclear cataract grade 1
and cortical grade 1.
Optical Coherence Tomography Evaluation The
evaluation of the integrity of ELM and EZ of the
photoreceptor interface, carried out at baseline, 6, 12 and
18mo, did not reveal alterations due to the dexamethasone
implant.
DISCUSSION
This study was performed to investigate the efficacy and
safety of Intravitreal Dexamethasone Implant (Ozurdex ® )
over time in patients affected by persistent DME.
The results, as previously reported[24], showed that Intravitreal
Dexamethasone Implant induced an improvement in BCVA,
and CMT values with an effect lasting 6mo. In addition, we
found that BCVA and CMT values did not return to the
baseline conditions during 18mo follow-up.
This study indicates that the Intravitreal Dexamethasone
Implant is both efficient and safe not only for the treatment of
secondary macular edema produced by branch retinal
vein occlusion (BRVO) and central retinal vein occlusion
(CRVO) [19-20], but also for secondary macular edema after
diabetic retinopathy [22]. In patients with persistent DME,
important functional (BCVA) and morphologic (CMT)
improvement of the retina in the treated eye were observed.
Our data suggest that the maximum effects of the
dexamethasone implant occur at 3mo and slowly decrease
from month 4 to 6. This finding is in line with previous
studies showing that the improvement of visual parameters
already starts from day three of the intravitreal implant and
decreases over time [25-28]. Our results also showed a similar
clinical course after the second and the third dexamethasone
reinjection, although at the end of the follow-up the BCVA
and CMT values were improved persistently when compared
to the baseline values. This cyclic trend may be due to a
reduced release of the drug over time. Thus, one can
hypothesize that the gradual decrease of the efficacy may be
due to reduced concentrations of dexamethasone in the
vitreous. Alternatively, it is possible that the chronic nature of
this illness may limit the efficacy of the implant over time.
Other studies are necessary to elucidate this mechanisms[29].
Nonetheless, despite this effect, our data support the notion
that intravitreal corticosteroids may represent an effective
treatment for DME, not only to prevent visual loss, but also
to recover of visual acuity [18,30]. These agents have
anti-inflammatory and anti-angiogenic properties stabilizing
the inner blood-retina barrier and act on all inflammatory
mediators. Corticosteroids modulate their effects by
interacting with specific nuclear steroid-hormone-receptors.
These receptors mainly reside in the cytoplasm in an inactive
form until steroid binding, receptor activation and
translocation to the nucleus [31]. Although corticosteroids
predominantly act by increasing gene transcription, there are
well-documented examples showing that glucocorticoids
decrease gene transcription[7]. Previous study[6] has shown that
intravitreal injection of dexamethasone improves DME by
inhibiting leukostasis and decreasing synthesis and
expression of ICAM-1. In addition, corticosteroids may
exert some of their immediate effects by non-genomic
mechanisms [32]. Moreover, it has been shown that activation
of glucocorticoid receptor protects the retinal photoreceptors
and has anti-apoptotic action[33].
The greater efficacy of dexamethasone in DME patients
resistant to anti-VEGF therapy may be due to the
characteristic of the implant that, unlike anti-VEGFs, allows
a stable release of 0.7 mg of preservative-free dexamethasone
into the vitreal chamber [19,21,25,27]. The administration route is
essential for the therapeutic efficacy of steroids. In fact, oral
steroid administration may cause systemic side effects and,
above all, the concentration of steroid in the vitreous is very
low[14]. Instead, the use of drugs administered directly into the
vitreous allows achieving appropriate concentration at the
site of disease, with minor systemic side effects[5,34].
Interestingly we observed that repeated injections of
dexamethasone did not induce serious side effects, a finding
in line with other studies[17,19,22,27-28,35]. None of our patients had
uncontrolled hypertension, hyperlipidemia, renal disease, or
other comorbidities during the follow-up period. An increase
in IOP that occurred in 15% ( =5) of patients was easily
handled with an antiglaucomatous mono-therapy.
Dexamethasone implant has also lower incidence of cataract
and glaucoma than other steroids[17].
In conclusion, our findings demonstrate that Intravitreal
Dexamethasone Implant (0.7 mg) improves BCVA and has a
safety profile consistent with previous data [20,36] in DME
patients resistant to anti-VEGF therapy. Our data also show
that the use of drugs administered directly into the vitreous
allows achieving appropriate and long-lasting concentration
at the site of disease without systemic side effects, with the
final aim to improve therapeutic response and reduce the rate
for re-treatment. The use of steroids in DME patients
represents an alternative therapeutic strategy in cases where
other therapies (laser or anti-VEGF) have failed [24,37-39].
Nonetheless, other studies are necessary to confirm these
data.
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